The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Top Cited Papers
- 15 September 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (18) , 5268-5272
- https://doi.org/10.1158/1078-0432.ccr-05-1554
Abstract
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.Keywords
This publication has 57 references indexed in Scilit:
- Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationThe EMBO Journal, 2006
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorPublished by Elsevier ,2006
- Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptorsGenes & Development, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Mutations of the BRAF gene in human cancerNature, 2002